B+
Bull case
20%
Probability
Target price
$23.00
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
CRVS
CorvusCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Soquelitinib has multiple shots on goal across PTCL, atopic dermatitis, asthma, hidradenitis suppurativa, and China development. Enrollment is reported on track, early atopic dermatitis data remain supportive, and cash runway extends into Q2 2028.
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +8.3.
What can break
Late-2026 China, asthma, and hidradenitis suppurativa milestones may be delayed or produce inconclusive data.
Momentum
38
Value
41
Sentiment
61
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $12.50 · Bull $23.00 · Bear $7.50Analysis 2026-08-08; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-08-08 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $33.14
Why
Momentum38 · Δ7d -9.7
Value41 · Δ7d 0.0
Sentiment61 · Δ7d +8.3
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +8.3.
Contradictions & invalidation
- • Late-2026 China, asthma, and hidradenitis suppurativa milestones may be delayed or produce inconclusive data.
- • No reliable analyst revision, consensus surprise, or post-print market-reaction attribution was available.
- • The thesis remains clinical and binary, with no validated consensus surprise, analyst revision, or target-change signal in the packet.
Catalyst clock
2026-08-06
Q2 update preserved clinical execution and runway
Lead driver: Sentiment · See AI snapshot
Momentum
38
9% active weight
Current posture
7d trendSoftening
Δ7d
-9.7
Δ21d
-37.5
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
+0.1
Sentiment
61
62% active weight
Current posture
7d trendImproving
Δ7d
+8.3
Δ21d
+9.4
Why this grade
Composite grade C. Momentum 37.9 / Value 41.2 / Sentiment 61.4
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-08-08. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$12.50
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$7.50
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$1.25B
Beta
0.70
Shares Out
84.12M
P/E (TTM) · Derived
-77.1
P/S (TTM)
-
P/FCF (TTM) · Derived
-28.90
Rev YoY
-
EPS YoY
+89.1%
Gross Margin
-
Op Margin
-
Net Debt
-$55.81M
Current Ratio
16.16
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data